A detailed history of Huntington National Bank transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Huntington National Bank holds 573 shares of KRYS stock, worth $109,099. This represents 0.0% of its overall portfolio holdings.

Number of Shares
573
Previous 290 97.59%
Holding current value
$109,099
Previous $53,000 96.23%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$174.7 - $213.66 $49,440 - $60,465
283 Added 97.59%
573 $104,000
Q2 2024

Aug 08, 2024

BUY
$153.12 - $183.64 $7,196 - $8,631
47 Added 19.34%
290 $53,000
Q1 2024

May 03, 2024

BUY
$108.01 - $179.35 $25,274 - $41,967
234 Added 2600.0%
243 $43,000
Q2 2023

Aug 11, 2023

BUY
$78.48 - $130.32 $706 - $1,172
9 New
9 $1,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.89B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.